| Revenue growth | 6.4% YoY for FY26; underlying growth 10% excluding access markets. |
|---|---|
| Margins | EBITDA margins expanded 140bps YoY to 19%; targeting 20% upwards. |
| Demand visibility | Strong in Ex-U.S. markets; U.S. growth expected H2 FY27 onwards. |
| Management confidence | High; citing structural shift to diversified, resilient portfolio and operational discipline. |
Growth
FY26 revenue grew 6.4% to ₹48,587M; EBITDA grew 15% to ₹9,250M with 19% margins. Operational PAT rose 50%.
Outlook
Guided U.S. revenue of $375M-$400M by FY28. Targeting EBITDA margins 20%+ and gross margins 58-60%.
Risks
Geopolitical environment, logistical cost spikes (₹200M in Q4), and a weak U.S. flu season impacted seasonal revenue.
Earnings Call filed with NSE, NSE: STAR. Summary written with AI assistance from the document.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,184.90
- Market cap
- ₹10,922 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 17.8×Sector 50.4×
- Promoter holding
- 27.91%+0.00% QoQ
- FII holding
- 28.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Business Update
Strides Pharma Science received a Form 483 with three observations following a routine USFDA inspection at its Alathur formulations facility. The company will respond within stipulated timelines.
Strides Pharma Science Earnings Call Transcript: Key Takeaways
Strides Pharma Science reported Q1 FY27 results with 13% YoY revenue growth and EBITDA margins maintained at 18.2%. Strategy focuses on Ex-US growth and US portfolio diversification.
- Call
- Guides 32% growth
Strides Pharma Science Investor Presentation: Key Takeaways
Strides Q1FY27 revenue grew 13% YoY to ₹12,654m, led by a 17% surge in Ex-US markets. Operational PAT stood at ₹1,231m.
Strides Pharma Science Q1 FY27 Results: Net Profit ₹165.5 Cr, Up 56.7% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,265 Cr (+13.0% YoY) and net profit of ₹165.5 Cr (+56.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹165.5 Cr · +56.7% YoY
Strides Pharma Science Earnings Call: Key Takeaways
Strides delivered strong FY26 performance with Revenue at ₹48,587m, up 6.4%, and Operational PAT at ₹5,181m, growing 50% YoY driven by Ex-US market efficiency.
Strides Pharma Science Q4 FY26 Results: Net Profit ₹129.3 Cr, Up 51.1% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,324 Cr (+11.2% YoY) and net profit of ₹129.3 Cr (+51.1% YoY) for Q4 FY26.
- Key figure
- Net profit ₹129.3 Cr · +51.1% YoY